Mr. Jeff Zygouras reports

NEUPATH HEALTH ANNOUNCES RENEWAL OF NORMAL COURSE ISSUER BID

The TSX Venture Exchange has accepted a notice filed by Neupath Health Inc. of the company's intention to renew its normal course issuer bid.

Under the NCIB, the company may, during the 12-month period commencing Dec. 4, 2025, and ending Dec. 3, 2026 (or on such date that the company completes its purchases or provides notice of termination), purchase up to 2,527,224 common shares in total, being approximately 4.5 per cent of the total number of shares outstanding as at Dec. 3, 2025, being 56,160,537 shares. The price which the company will pay for any such shares will be the prevailing market price at the time of acquisition. Also, in accordance with the policies of the exchange, the company may not purchase more than 2 per cent of its issued and outstanding shares during any 30-day period. The actual number of shares which may be purchased pursuant to the NCIB and the timing of any such purchases, outside of restricted periods, will be determined by management of the company.

Purchases under the NCIB will be made from time to time by Acumen Capital Finance Partners Ltd. on behalf of the company through the facilities of the exchange or through a Canadian alternative trading system. The company has entered into a predefined plan with the broker to allow for the purchase of shares under the NCIB at times when the company ordinarily would not be permitted to purchase shares due to its internal trading blackout periods, insider trading rules or regulatory restrictions. The plan provides a set of standard instructions to the broker to make purchases at its sole discretion under the NCIB in accordance with the terms set out in such plan, the rules of the exchange and applicable securities laws. Decisions regarding any future repurchases will depend on certain factors, such as market conditions, share price and instructions set forth in the plan. The company may elect to suspend or discontinue share repurchases at any time in accordance with the plan and applicable laws.

Under Neupath's prior NCIB, which commenced on Nov. 27, 2024, and ended on Nov. 26, 2025, the company obtained approval to purchase up to a total of 2,820,044 shares, of which 1,052,300 shares were purchased for cancellation through the facilities of the exchange at a volume-weighted average price of approximately 24 cents (excluding commissions) per share as of Nov. 24, 2025.

To the knowledge of the company, no director, senior officer or other insider of the company, or any of their associates, or any associates or affiliates of the company, currently intend to sell shares under the NCIB. All share purchases will be made on the open market through the facilities of the exchange and will be purchased for cancellation. The financing for any purchase pursuant to the NCIB will be financed out of the working capital of the company.

The board of directors believes the underlying value of the company may not be reflected in the current market price of its shares. As a result, depending upon future price movements and other factors, the board believes that the purchase of shares may represent an attractive investment to the company and in the best interests of the company. Furthermore, the purchases are expected to benefit all persons who continue to hold shares by increasing their equity interest in the company if the repurchased shares are cancelled.

About Neupath Health Inc.

Neupath operates a network of health care clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centred multidisciplinary care. It operates a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries and concussions. In addition, Neupath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of health care providers, as well as contract research services to pharmaceutical and biotechnology companies. Neupath is focused on enabling individuals to live their best life.

We seek Safe Harbor.